LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML) concerning possible violations of federal securities laws.
On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.
When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.